PMID: 21527062Apr 30, 2011

Next generation of antibody therapy for cancer

Chinese Journal of Cancer
Zhenping Zhu, Li Yan

Abstract

Monoclonal antibodies (mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases. To date, 15 mAbs have been approved by regulatory agencies in the world for clinical use in oncology indications. The selectivity and specificity, the unique pharmacokinetics, and the ability to engage and activate the host immune system differentiate these biologics from traditional small molecule anticancer drugs. mAb-based regimens have brought clinical benefits, including improvements in overall survival, to patients with a variety of cancers. Many challenges still remain, however, to fully realize the potential of these new medicines. With our further understanding of cancer biology, mechanism of antibody action, and advancement of antibody engineering technologies, many novel antibody formats or antibody-derived molecules are emerging as promising new generation therapeutics. Carefully designed and engineered, they retain the advantage of specificity and selectivity of original antibodies, but in the meantime acquire additional special features such as improved pharmacokinetics, increased selectivity, and enhanced anticancer efficacy. Promising clinical results are being generat...Continue Reading

References

Aug 15, 1991·Nature·T ClacksonG Winter
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C QueenT A Waldmann
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S L MorrisonV T Oi
Feb 7, 2001·Cancer Immunology, Immunotherapy : CII·D ShanO W Press
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R I NicholsonM E Harper
Jan 5, 2002·Current Pharmaceutical Biotechnology·C Krasner, R M Joyce
Dec 31, 2003·The Journal of Biological Chemistry·Paul R HintonNaoya Tsurushita
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy MillerHope S Rugo
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Greg A LazarBassil I Dahiyat
Jun 24, 2006·The Journal of Biological Chemistry·William F Dall'acquaHerren Wu
Jun 27, 2006·Immunology Letters·Sophie SibérilJean-Luc Teillaud
Dec 1, 2006·The Journal of Biological Chemistry·Amita Datta-MannanVictor J Wroblewski
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioEastern Cooperative Oncology Group Study E3200
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Oct 19, 2007·Cancer Treatment Reviews·Roberto StasiSergio Amadori
Nov 13, 2007·Drug Discovery Today·John R DesjarlaisSeung Y Chu
Nov 16, 2007·The New England Journal of Medicine·Derek J JonkerMalcolm J Moore
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Mar 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael G AmadoDavid D Chang
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Apr 4, 2008·Pharmacogenomics·Joanne Cross
Jun 10, 2008·The Cancer Journal·Paul J Carter, Peter D Senter
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Nov 18, 2008·Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Feb 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckChristian Manegold
Mar 3, 2009·Molecular Immunology·Vaheh OganesyanWilliam F Dall'acqua
Aug 13, 2009·The New England Journal of Medicine·Matthew R SmithDenosumab HALT Prostate Cancer Study Group
Jan 5, 2010·MAbs·Li YanRobert A Beckman
Jan 19, 2010·Nature Biotechnology·Jonathan ZalevskyJohn R Desjarlais
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaLuca Gianni
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WierdaHx-CD20-406 Study Investigators
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson
Jul 6, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven J LemeryRichard Pazdur
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison T StopeckAda Braun
Dec 3, 2010·Expert Opinion on Investigational Drugs·Stephen M Ansell
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A BurrisJoyce O'Shaughnessy

Citations

Dec 16, 2017·Scientific Reports·Manuel BrehsChristian F W Becker
Jul 7, 2019·International Journal of Molecular Sciences·Arathi NairKatharina F Kubatzky
Dec 11, 2020·Expert Opinion on Biological Therapy·Theodoros MichelakosSoldano Ferrone

Related Concepts

VEGF165 protein, human
TNFSF11 protein, human
EGFR protein, human
Monoclonal Antibodies
Malignant Neoplasms
Epidermal Growth Factor Receptor
Protein Engineering
ErbB-2 Receptor
Radioimmunoconjugates
CD20 Antigens

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Computational Methods for Protein Structures

Computational methods employing machine learning algorithms are powerful tools that can be used to predict the effect of mutations on protein structure. This is important in neurodegenerative disorders, where some mutations can cause the formation of toxic protein aggregations. This feed follows the latests insights into the relationships between mutation and protein structure leading to better understanding of disease.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.